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Abstract: Introduction: Two recent studies have highlighted low rates of virological response to once daily nevirapine 
containing combination antiretroviral therapy (CART) in treatment naïve HIV-1 infected subjects. 
Aim: We assessed factors associated with treatment responses in a cohort of HIV-1 infected, therapy naïve individuals, 
commencing nevirapine CART with two nucleoside reverse transcriptase inhibitors (NRTI) containing either lamivudine 
or emtricitabine. 
Results: Between January 2002 and 2006, 173 subjects (80 female) met the study inclusion criteria. All subjects initially 
commenced on twice daily nevirapine with six different NRTI backbones. Mean follow up was 802 days. 49 (28%) sub-
jects switched to once daily nevirapine, 23 (13%) within the first year. After 48 weeks of therapy, HIV RNA was < 50 
copies/mL in 154/173 subjects (89%). A trend was observed towards improved virological outcome (HIV RNA < 50 
copies/mL) and switching to once daily nevirapine during the first year of therapy (p=0.051). 
Conclusion: Whilst awaiting the results of prospective studies assessing once daily nevirapine, our data describe high 
treatment success rates and good safety responses when switching to once daily nevirapine. 
INTRODUCTION 
  Many different initial therapeutic options are available 
for HIV-1 infected subjects commencing combination 
antiretroviral therapies (CART). Recommendations from 
current treatment guidelines include the use of a non-
nucleoside reverse transcriptase inhibitor (NNRTI) with a 
nucleoside reverse transcriptase inhibitors (NRTI) backbone 
[1]. 
  Adherence to CART regimens remains paramount in the 
long term virological success of therapy and strategies to 
simplify CART, such as once daily dosing of therapy, may 
improve adherence [2]. Nevirapine, a frequently prescribed 
NNRTI as part of CART regimens, is currently licensed as a 
twice daily agent. 
  The pharmacokinetic characteristics of nevirapine in-
clude a long plasma elimination half life of 25-30 hours in 
steady state, suggesting once daily dosing may feasible in 
clinical practice. Indeed formal pharmacokinetic studies in 
HIV-1 infected subjects have demonstrated no significant 
difference in total nevirapine plasma exposure when dose 
once daily or twice daily [3] however median nevirapine 
plasma concentration at the end of dosing interval was 23% 
lower in the once daily dosing group. 
  Two recent studies have highlighted low rates of viro-
logical response to once daily nevirapine regimens [4, 5] in  
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therapy naïve HIV-1 infected subjects. The DAUFIN study 
[4] compared the combination of nevirapine, zidovudine, 
lamivudine dosed at 200, 250, 150 mg twice daily versus 
nevirapine, lamivudine, tenofovir dosed at 400, 300, 245 mg 
once daily, respectively. This study was prematurely termi-
nated after enrolling 71 subjects. The once daily arm resulted 
early virological failure with a high rate of HIV viral resist-
ance. 
  However, in clinical practice, nevirapine is often dosed in 
once daily schedules after an initial lead-in period of twice 
daily therapy. We therefore aimed to determine factors asso-
ciated with successful treatment outcomes in therapy naïve 
patients commencing on nevirapine containing CART in a 
large UK urban centre. 
METHODS 
  All HIV-1 infected, antiretroviral naïve patients, com-
mencing on nevirapine containing CART with lamivudine or 
emtricitabine plus one other nucleoside analogue at the de-
partment of HIV Medicine, St. Mary’s Hospital London be-
tween January 2002 to January 2006 were eligible for this 
study. Subjects commencing any nevirapine dosing schedule 
were included and were required to have been on therapy for 
at least one year to be eligible. Exclusion criteria included 
baseline NRTI or NNRTI resistance and concomitant medi-
cations which may interact with nevirapine plasma concen-
tration such as rifampicin. 
  Routine data on individuals who attend our department 
are collected at each clinic visit in our prospective clinic da-
tabase. These data include demographic data, antiretroviral 90    The Open AIDS Journal, 2008, Volume 2  Benzie et al. 
therapy history and laboratory parameters. Data downloaded 
for this analysis included a full dataset to 01 January 2007. 
  From this database antiretroviral history was collected. 
Baseline was considered the time CART was commenced. In 
addition, we collected the following data for each clinic visit 
from baseline until January 2007 (thereby providing the 
range of follow period for this cohort of a minimum of one 
year to a maximum of five years); CD4 lymphocyte count 
(cells/uL), plasma HIV RNA (copies/mL), serum alanine 
aminotransferase (ALT) and total cholesterol. 
Statistical Analyses 
  All statistical calculations were performed using SPSS 
for Windows version 14.0. Factors associated with virologi-
cal response, changes in CD4+ lymphocyte count and chan-
ges in total cholesterol over 48 weeks were assessed in a 
univariate model by linear regression. The potential predic-
tors assessed were baseline and nadir CD4+ cells/L, gen-
der, baseline HIV RNA log10 copies/mL, NRTI backbone 
and switching NRTI backbone or to once daily nevirapine in 
the first year of therapy. Multivariate analyses were per-
formed on parameters in univariate models with p-values 
less than 0.10, using a stepwise-forward method. 
RESULTS 
Baseline 
  During this four year period, 173 previously therapy na-
ive HIV-1 infected subjects commenced a nevirapine con-
taining CART regimen and were eligible for the analysis. All 
patients commenced on twice daily nevirapine initially. 
Baseline characteristics are shown in Table 1. Within this 
cohort, six different initial NRTI backbones were prescribed 
based on clinician choice with zidovudine-lamivudine the 
most frequently used (68%) reflecting prescribing practices 
at this time. 
Patient Follow Up, Virological and Immunological Re-
sponses 
  Total patient follow up on nevirapine in this cohort repre-
sents 380 person years. Mean (range) follow up from the 
start of nevirapine to the last date when data analysis per-
formed was 802 (60 -1824) days. At week 48, 85% of sub-
jects had a viral load < 50 copies/mL and a mean CD4 cell 
count increase of 204 cells/L. Follow up parameters over 
the five year period are shown in Table 2. 
Changes to Antiretroviral Therapy 
  Over the five year study period, forty-nine (28%) of sub-
jects switched from twice daily to once daily nevirapine dos-
ing, with a median time to switch of 576 days. Of interest, all 
subjects had an undetectable plasma HIV RNA prior to this 
switch and 23 (13%) of subjects switched to once daily nevi-
rapine during the first year of therapy at a mean (SD) time of 
140 (107) days. 
  Forty-two subjects (24%) ceased nevirapine CART 
which was due to virological failure in 11 and physician de-
Table 1.  Patient Characteristics, Baseline Antiretroviral Therapy 
 
   Number  (%)  Unless  Otherwise  Stated 
Baseline Characteristics      
Number of Patients    173  (100.00) 
Gender male  93  54.0 
   female  80  46.0 
NRTI Backbone (baseline)  AZT +3TC  117  (68.0) 
   TDF + 3TC  17  (10.0) 
   ABC + 3TC  11  (6.0) 
   d4T + 3TC  2  (1.0) 
   ddI + 3TC  1  (1.0) 
   TDF + FTC  25  (14.0) 
CD4 nadir (cells/uL), mean (range)    170  (10 - 490) 
CD4 at start of nevirapine (cells/uL), 
mean (range) 
overall 
male 
female 
207 
214 
201 
(10 - 540) 
(20 - 540) 
(10 - 520) 
Male with baseline CD4+ > 400 cells/uL 
Female with baseline CD4+ > 250 cells/uL 
 4 
16 
4 
20 
Ethnicity Caucasian 
African origin 
Other 
131 
39 
3 
76 
22 
2 
Viral load at start of CART 
(log10 copies/mL), mean (range) 
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cision in the remaining group. Mean time to ceasing nevirap-
ine was 252 days (range 110 - 1184). Interestingly, no pa-
tients ceased nevirapine after switching to a once daily regi-
men. Neither gender, baseline CD4 lymphocyte count or 
ALT at week 8 were significantly associated with ceasing 
nevirapine CART. 
  Changes to NRTI backbones were frequently observed in 
this cohort with 76 (44%) of the cohort undergoing at least 
one switch. This was predominantly in subjects commencing 
on a zidovudine containing regimen with 58 of 117 subjects 
(50%) switching in this group. 
Factors Associated with Virological Response and 
Changes in Laboratory Parameters Over 48 Weeks 
  Factors associated with an undetectable plasma HIV 
RNA to less than 50 copies/mL at week 48 are shown on 
Table  3. Although no parameter was statistically signifi-
cantly associated with virological response, both baseline 
viral load and switching to once daily nevirapine in the first 
year of therapy had p-values below 0.10 in univariate and 
multivariate analyses. 
  No associations were observed between the NRTI back-
bones most frequently prescribed at baseline in this cohort 
and changes in CD4 lymphocyte count, total plasma choles-
terol over 48 weeks or having an undetectable plasma HIV 
RNA at week 48. During the first year of therapy, seven sub-
jects switched NRTI backbone, all from a zidovudine con-
taining regimen. When excluding these subjects from this 
analysis, no significant associations were observed with the 
above parameters. 
  Furthermore, no significant association between changes 
in alanine aminotransferase (ALT) and switching to once 
daily nevirapine were observed at weeks 8, 24 or 48 (p-
values above 0.20 all analyses). 
DISCUSSION 
  In this study, high treatment success rates were observed 
in subjects receiving nevirapine containing CART regimens 
including once daily nevirapine regimens; overall total pa-
tient follow up represented 380-patient-years, and low rates 
of virological failure were observed (6.3%). Female subjects 
are often under-represented in studies assessing antiretroviral 
treatment responses and gender differences are often not 
addressed. Our data is of importance as 46% of our cohort 
were female, with no gender differences in treatment re-
sponses observed. 
  Although numbers were small, there was a trend towards 
improved outcomes (p=0.051, multivariate analysis) using 
once daily nevirapine containing regimens. This may be as-
sociated with the improved adherence and tolerability of 
once daily antiretroviral therapy compared to more frequent 
dosing schedules [2]. 
  Several factors may explain the high treatment success 
rates observed with once daily nevirapine dosing in this co-
hort, compared to other studies [4]. Firstly all subjects were 
commenced on twice daily nevirapine as initial CART 
therapy, and then switched to once daily dosing. Prospective 
studies are needed to assess once daily nevirapine as initial 
antiretroviral therapy and two international randomised con-
trolled trials are currently underway. Secondly, all subjects 
in our study had no documented NNRTI resistance at base-
line, whereas baseline resistance data have not been pre-
sented for all subjects in other studies [5]. 
  Low rates of success of once daily nevirapine in therapy 
naïve subjects has been associated with a high baseline viral 
load (above 100 000 copies/mL) [5]. This result was not re-
peated in our study where baseline characteristics, in terms 
of mean baseline viral load 4.98 log10 copies/mL (95 000 
copies/mL), and nadir CD4+ lymphocyte count 170 cells/L, 
were comparable. Furthermore, many different NRTI back-
bones have been assessed in our cohort, including 17 sub-
jects (10%) who commenced therapy with the NRTI back-
bone tenofovir and lamivudine, with no sub-optimal viro-
logical response. 
  Studies have also reported increased rates of adverse 
events with the use of once daily nevirapine, both in treat-
ment naïve subjects [6-8] and as a switch strategy [9]. In 
general, the increased rates of toxicity observed in these 
studies leads to questions regarding the pharmacokinetic-
pharmacodynamic relationship between nevirapine plasma 
exposure and adverse events [10]. However, in the therapy 
naïve studies, these adverse events were predominantly ob-
served in subjects of Thai ethnicity [6] and in many of these 
studies, nucleoside backbones associated with greater tox-
icity profiles such as didanosine + stavudine [7, 8] or teno-
fovir + didanosine [9] have been utilised. Our study differs 
by describing data on subjects switching to once daily nevi-
Table 2.  Laboratory Parameters and Dosing Schedules Over Study Period 
 
Time on 
Nevirapine 
Total 
Number 
Detectable HIV RNA, 
>50 Copies/mL (%) 
Mean CD4 Count, 
Cells/uL (SD) 
Switch to Once Daily 
Nevirapine, n (%) 
ALT, 
IU(SD) 
Total Cholesterol, 
mmol/L (SD) 
HDL, 
mmol/L (SD) 
Baseline  173    232 (121)  -  27 (25)  3.98 (0.75)  1.08 (0.30) 
Week 8  173      -  60 (11)  -   
One year  169  15 (8.7)  362 (159)  23 (13.3)  28 (19)  4.89 (1.0)  1.40 (036) 
Two years  129  8 (6.2)  388 (183)  9 (5.2)  31 (24)  4.96 (0.8)  1.46 (0.44) 
Three years  84  7 (8.3)  466 (200)  6 (3.5)  39 (33)  4.96 (1.1)  1.47 (0.50) 
Four years  52  2 (3.8)  402 (207)  8 (4.6)  36 (26)  5.09 (0.96)  1.43 (0.46) 
Five years  22  1 (4.5)  418 (186)  2 (1.2)  24 (13)  -   92    The Open AIDS Journal, 2008, Volume 2  Benzie et al. 
rapine in combination with nucleoside backbones containing 
either lamivudine or emtricitabine, the NRTI backbones rec-
ommended in current treatment guidelines [1]. Interestingly, 
no toxicity related treatment discontinuation was observed in 
our cohort in subjects switching to once daily nevirapine. 
  Frequently observed adverse events associated with nevi-
rapine use include rash and hepatotoxicity. Safety analyses 
of nevirapine in different populations of HIV infected pa-
tients [11] with the recognition of a relationship between 
hepatotoxicity and CD4+ lymphocyte count lead to modifi-
cation of nevirapine prescribing recommendations [12]. In 
our cohort, 4 (4%) male and 16 (20%) female subjects com-
menced nevirapine prior to the introduction of these recom-
mendations (CD4+ lymphocyte count < 400 and <250, for 
male and female subjects, respectively), however no in-
creased rates of toxicity were observed, probably due to 
small numbers. 
  Limitations of this study include the retrospective cohort 
nature of the data and no therapeutic drug monitoring per-
formed to assess plasma exposure of once daily nevirapine in 
our cohort. Furthermore many subjects switched NRTI 
backbone during the study period, and although switching 
NRTI therapy from thymidine analogues is in keeping with 
current clinical practice, this is a un-controlled variable in 
our analysis. Whilst awaiting the results of prospective stud-
ies assessing once daily nevirapine, data from this study sug-
gests that switching to once daily nevirapine containing 
regimens results in durable virological responses, is safe and 
well tolerated. 
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